Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ten Months On, Abbott, Wockhardt Terminate Deal For Nutritional Business

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Pharmaceuticals-to-diagnostics giant Abbott and debt-ridden Indian drug maker Wockhardt jointly agreed to call off the $130 million deal for a nutritional business that the two had announced barely 10 months ago

You may also be interested in...



INTERVIEW: Abbott Nutrition Revs Up For Bigger India Play

A combination of factors is aiding Abbott Nutrition’s pitch for a bigger slice of the evolving Indian nutrition market. The company is already growing at a rate far higher than the industry average of 12%, a pace it expects to maintain for the next few years.

INTERVIEW: Abbott Nutrition Revs Up For Bigger India Play

A combination of factors is aiding Abbott Nutrition’s pitch for a bigger slice of the evolving Indian nutrition market. The company is already growing at a rate far higher than the industry average of 12%, a pace it expects to maintain for the next few years.

Danone Gets Second Time Lucky, Buys Wockhardt's Nutrition Brands That Abbott Had Won And Lost

HYDERABAD, India - After several months of discussions, debt-laden Indian drug maker Wockhardt Ltd. finally managed to sell its growing nutritional business to French food giant Group Danone for reportedly $354 million - a quantum jump from the $130 million that Abbott Laboratories Ltd. had agreed to pay for the same assets exactly two years ago

Related Content

UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel